Merck and Ridgeback’s molnupiravir offer hope to Covid-19 patients
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
The global wellness market is valued at more than US $ 1.5 trillion, with annual growth of 5-10 per cent
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
Remote screening of diabetic retinopathy can help in early detection, even before there are any noticeable vision changes
The two startups will utilise the capital for business growth including strategic expansion, product development, R&D and technology investments
Over 61 per cent of pharmacists stated that they aim to improve their knowledge and medical skills while 76 per cent collaborated with healthcare players to improve the outcome for their patients
This procedure is incidentally the first robotic bariatric surgery in the world to be performed in just three ports
Barbara Engelhardt moves her computational and statistics lab to Gladstone
Between 30-40 per cent of Covid-19 patients are either obese or diabetic
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
Subscribe To Our Newsletter & Stay Updated